åêðáéäåõóçó γ.ν.α.

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 71, ΣΥΜΠΛΗΡΩΜΑ, 2009
505
Respiration.html
11. Johnstone RW, Ruefli AA, Loewe SW: Apoptosis: a
link between cancer genetics and chemotherapy. Cell
2002;108: 153-64.
12. Ward TH, Cummings J, Dean E et al: Biomarkers of
apoptosis. Br J Cancer 2008; 99: 841-846.
13. Holdenrieder S, Stieber P, von Pawel J et al: Circulating
nucleosomes predict the response to chemotherapy in
patients with advanced non-small cell lung cancer. Clin
Cancer Res 2004; 10: 5981-87.
14. Moll R, Divo M, Langbein L: The human keratins: biology
and pathology. Histochem Cell Biol 2008; 129:
705-733.
15. Oshima R.G: Intermediate filaments: a historical perspective.
Exp Cell Res. 2007; 313(10): 1981-1994.
16. Marceau N, Loranger A, Gilbert S et al: Keratin mediated
resistance to stress and apoptosis in simple epithelial
cells in relation to health and disease. Biochem Cell Biol
2001; 79: 543-55.
17. Barak V, Goike H, Panaretakis K et al: Clinical utility of
cytokeratins as tumor markers. Clinical Biochemistry
2004;37: 529-40.
18. Bodenmόller H, Donie M, Kaufmann D et al: The tumor
markers TPA, TPS, TPS(CYK) and CYFRA 21.1 react different
with the keratins 8, 18 and 19. Int J Biol Markers
1994; 9:70-74.
19. Van Dalen A: Significance of cytokeratin markers TPA,
TPA(CYK), TPS and CYFRA 21.1 in metastatic disease.
Anticancer Res.1996;16:2345-2350.
20. Weber K, Osborn M, Moll R et al: Tissue polypeptide
antigen (TPA) is related to the non epidermal keratins
8,18 and 19, typical of simple and non squamous epithelia:
a re-evaluation of a human tumor marker. EMBO
J 1984; 3: 2707-14.
21. Mellerick DM, Osborn M & Weber K: On the nature of
serological tissue polypeptide antigen (TPA); monoclonal
keratin 8, 18 and 19 antibodies react differently with
TPA prepared from human cultured carcinoma cells and
TPA in human serum Oncogene 1990; 5:1007-1017.
22. Bjφrklund B: On the nature and clinical use of Tissue
Polypeptide Antigen. Tumor Diagnostik Ther 1980;1:
9-20.
23. Bjőrklund B: Tumour markers TPA, TPA-S and cytokeratins.
A working hypothesis. Tumordiagn Ther 1992;
13:78-80.
24. Rydlander L, Ziegler E, Bergman T et al: Molecular
characterization of a tissue-polypeptide-specific-antigen
epitope and its relationship to human cytokeratin 18.
Eur J Biochem 1996; 241: 309-314.
25. Björklund B, Björklund V: Specificity and basis of the
tissue polypeptide antigen. Cancer Detect Prev 1983;
6: 41-51.
26. Marrink J: TP(A) or not TP(S): what’s the question
Tumour Marker Update 1993; 5(4):71-73.
27. Sundström BE, Stigbrand TI: Cytokeratins and tissue
polypeptide antigen. Int J Biol Markers 1994; 9(2):
102-8.
28. Fernandes LC, Kim SB, Saad SS et al: Value of carcinoembryonic
antigen and cytokeratins for the detection
of recurrent disease following curative resection of
colorectal cancer. World J Gastroenterol 2006; 12(24):
3891-4.
29. van Dalen A, van der Linde DL, Heering KJ et al: How
can treatment response be measured in breast cancer
patiets: Anticancer Res 1993; 13: 1901-4.
30. Stieber P, Dienemann H, Hasholzner U et al: Comparison
of CYFRA 21.1, TPA and TPS as tumour markers in
lung cancer. Eur J Clin Chem Clin Biochem 1993; 31
689-694.
31. Rastel D: Measurement of cytokeratin 19 fragments in
serum: clinical application of a tumour marker called
CYFRA 21.1. Tumour marker update; 1995;7:55-63.
32. Kandiloros D, Eleftheriadou A, Chalastras T et al: Prospective
study of a panel of tumor markers as prognostic
factors in patients with squamous cell carcinoma of
head and neck. Med Oncol. 2006; 23(4):463-70.
33. Ishii T, Bandoh S, Fujita J et al: A full-length cytokeratin
8 is released and circulates in patients with non-small
cell lung cancer. Tumour Biol 2008; 29(1):57-62.
34. Omary MB, Ku NO, Liao J et al: Keratin modifications
and solubility properties in the epithelial cells and in
vitro. Subcell Biochem 1998; 31:105-40.
35. Sheard MA, Vojtesek B, Simickova M et al: Release of
cytokeratin-18 and -19 fragments (TPS and CYFRA21-
1) into the extracellular space during apoptosis. J Cell
Biochem 2002; 85(4): 670-77.
36. Leers MP, Kölgen W, Björklund V et al: Immunocytochemical
detection and mapping of a cytokeratin 18
neo-epitope exposed during early apoptosis. J Pathol
1999; 187: 567-72.
37. Linder S: Cytokeratin markers come of age. Tumour
Biol 2007; 28(4):189-95.
38. Olofsson MH, Ueno T, Pan Y et al: Cytokeratin-18 is
a useful serum biomarker for early determination of
response of breast carcinomas to chemotherapy. Clin
Cancer Res 2007; 13(11): 3198-3206.
39. Bradshaw HD Jr, Deininger PL: Human thymidine gene:
molecular cloning and nucleotide sequence of a cDNA
expressible in mammalian cells. Mol Cell Biol 1984; 4:
2316-20.
40. Sherley JL, Kelly TJ: Regulation of human thymidine
kinase during the cell cycle. J Biol Chem 1988; 263:
8350-8.
41. a.Thymidine kinase, a new cancer diagnostic marker.
εύρεση στο δικτυακό τόπο: http://www.celticbio.
com/thy.doc b. Tumor markers. εύρεση στο δικτυακό
τόπο: http://training.seer.cancer.gov/module_diagnostic/unito3_tumor_markers.html
c.Thymidine kinase.
εύρεση στο δικτυακό τόπο: http://www.wikipedia.
org/wiki/thymidine_kinase d.Gronowitz S, Fischer LN,